COMPANY

BioVolutions is a CRO servicing clients whose interests range from preformulation to clinical trial manufacturing. BioVolutions' mission is to save time and minimize costs required to obtain tox supplies and clinical trial material.

Limit your tech transfer to one single service provider

BioVolutions is your single service provider to develop your formulation and drug delivery system, enable technology transfer under GLP and obtain your Clinical Trial Material (CTM) under GMP.

BioVolutions built  a specific expertise and capabilities to develop a compelling offering  that optimizes your time and costs to obtain your Clinical Trial Material.

Minimize your formulation costs

BioVolutions helps clients to decrease their fixed costs by out-sourcing formulation services.

BioVolutions is your ideal partner to outsource your formulation developments by reducing your costs, accelerating your product development and complementing your expertise.

Enable technology transfer

BioVolutions provides project management to accelerate technology transfer to the Contract Manufacturing Organization (CMO).

BioVolutions has the experience and expertise for successful technology transfer in the context of GMP.  

Obtain your Clinical Trial Material

BioVolutions releases or rejects each batch of Clinical Trial Material based on a cumulative review of completed manufacturing records and other relevant information  

BioVolutions is responsible for releasing or rejecting each batch of Clinical Trial Material based on a cumulative review of completed manufacturing records and other relevant information.

Maximize your Revenues

BioVolutions maximizes your revenues by maximizing the therapeutic index of your molecules through formulation, analytic and in vitro testing in a GMP Laboratory.

Give your product a competitive edge

BioVolutions protects your revenues and market share by assessing the impact of patent expiration.

BioVolutions helps clients to protect their market share by creating a new product via reformulation of their current drug product. Drug Delivery technologies are the least expensive and most reliable way to diversify a product by expanding market penetration capabilities with a maximized Therapeutic Index.

Drug Delivery and Product Life Cycle select graph for more detail

Enable or accelerate market entry

Enabling more active substances to proceed to clinical trials and more products to reach the market.

BioVolutions develops a formulation with the intent of maximizing the therapeutic index by rapidly screening out problem formulations using various analytical, dissolution testing and in-vitro assays.

Formulation Impacts on the Product Life Cycle select graph for more detail

Capabilities

Maurizio Cattaneo, PhD founded BioVolutions to offer services originating from his many years of expertise in formulation development, drug delivery and analytical development. Dr. Cattaneo obtained his PhD at McGill University under the direction of Dr. Thomas W Chang, the pioneer of microencapsulation for medical applications. Dr. Cattaneo contribution to bioanalytical development centered on the development of new analytical assays based on amperometry and chemiluminescence.

Select Formulation and Drug Delivery Publications

• Cattaneo, M.V. and T.M.S. Chang, The potential of a Microencapsulated Urease-Zeolite Oral Sorbent for the Removal of Urea in Uraemia. Trans. Am. Soc. Artif. Intern. Organs  37:80-87, 1991.
• Cattaneo MV and Demierre MF. Biodegradable Chitosan for Topical Delivery of Retinoic Acid. Drug Del Tech 1:44-48, 2001
• Lewandrowski,  Kai-Uwe; Bondre; Shrikar; Trantolo; Debra J.; Cattaneo; Maurice V.; Gresser; Joseph D.; Wise; Donald L. (2003)  Tissue transplant coated with biocompatible biodegradable polymer. US Patent 6,551,355
• Lewandrowski; Kai-Uwe; Bondre; Shrikar; Trantolo; Debra J.; Cattaneo; Maurice V.; Gresser; Joseph D.; Wise; Donald L. (2005). Osteoinduction of cortical bone allografts by coating with biopolymers seeded with recipient periosteal bone cells. US Patent  6,899,107
• Cattaneo MV. Topical Delivery Systems Based on Polysaccharide Microspheres. (2005) In: Delivery System Handbook for Personal Care and Cosmetic Products. MR Rosen (Ed). William Andrew Publ. pp.273-28.

Analytical and In Vitro Assay Publications:

• Cattaneo, M.V., J.H.T. Luong and S. Mercille (1992). Monitoring glutamine in mammalian cell cultures using an amperometric biosensor. Biosens. Bioelectr. 7:329-334.
• Cattaneo, M.V. and J.H.T. Luong (1993). On-line chemiluminescence assay using FIA and fiber optics for urinary and blood glucose. Enz. Microb. Technol. 15:424-428
• Cattaneo, M.V. and J.H.T. Luong (1994) A stable water soluble tetramethylbenzidine:hydroxypropyl cyclodextrin inclusion complex and its application in enzyme assays. Anal. Biochem. 223:313-320, 1994.
• Luong, J.H.T, Male K.B. and M.V. Cattaneo. (1995). Method and System for Determining Bioactive Substances. US Patent No. 5,411,866.

Management:

Maurizio Cattaneo, Ph.D., Founder, President and CEO
Dr. Maurizio Cattaneo, Founder, President and Chief Executive Officer of BioVolutions Inc. has 15 years experience in formulation development and drug delivery. In 2005, Dr. Cattaneo founded BioVolutions to serve the pharmaceutical industry in contract formulation development and the CMC section of the IND. At BioVolutions, Dr Maurizio Cattaneo is in charge of GLP-compliance and quality control and oversees formulation development, analytics and in-vitro testing. In 1997, Dr Cattaneo founded  IVREA Pharmaceuticals Inc. to develop transdermal and topical products based on reformulating generic APIs. He invented and headed topical and transdermal drug delivery development of IVREA’s dermatological products. Previously Dr Cattaneo was a Director of Technology at Cambridge Scientific Inc. in the area of injectable implants and Research Officer at the National Research Council of Canada. Dr Cattaneo has been granted 6 U.S. patents and has numerous publications in formulation and drug delivery including “Cattaneo MV and Demierre MF. Biodegradable Chitosan for Topical Delivery of Retinoic Acid. Drug Del Tech 1:44-48, 2001”. Dr. Cattaneo received his Ph.D. in Chemical Engineering at McGill University from Professor Thomas H. Chang in the area of oral encapsulation.

Success Story:

By effectively increasing the Therapeutic Index by an order of magnitude of Johnson & Johnson RetinA® product, Dr Maurizio Cattaneo enabled IVREA Pharmaceuticals to implement a full product development program.

With the intent of improving the therapeutic index of a molecule, retinoic acid, with a known skin irritation profile and poor patient compliance. Dr. Cattaneo, reformulated the molecule and submitted the new formulation to J&J for evaluation. J&J confirmed that the new formulation exhibited bioequivalence as measured using the gold standard rhino mouse acne model while significantly reducing irritation as measured using the standard Draize irritation model.

BioVolutions is a member of Massachusetts Biotechnology Council